Fast Five Quiz: Precision Medicine and Genetic Testing for Colorectal Cancer

Ali Alqahtani, MD


June 17, 2022

RAS mutational testing, which should include KRAS and NRAS codons 12 and 13 of exon 2, 59 and 61 of exon 3, and 117 and 146 of exon 4 ("expanded" or "extended" RAS), must be performed in patients who are being considered for anti-EGFR receptor therapy. Clinical trial data have shown that patients with CRC carrying activating mutations of KRAS affecting exon 2 codons 12 and 13 did not benefit from anti-EGFR monoclonal antibody therapy.

Learn more about KRAS mutations in CRC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.